Stephen Hoffman and Josef Moosholzer, both formerly principals at Techno Venture Management (TVM), have been promoted to general partner and venture partner respectively.
Hoffman, who is a member of the Boston-based life science team, joined TVM in January 2003. He serves on the board of portfolio companies CyDex and Precision Therapeutics and is a board observer at Acorda Therapeutics and Sunol Molecular Corp. From 1994 to 2003, Hoffman was president, CFO and director of Allos Therapeutics, where he remains chairman.
“Stephen has been an outstanding addition to the life science team. His experience, network and understanding of how to build a life science company have been an invaluable addition to our practice,” said Helmut Schuesler, managing partner of TVM.
Hoffman’s promotion brings the number of general partners at TVM to 14, including two managing partners. Five of the general partners are members of the life science team.
Moosholzer, who leads the firm’s accounting and controlling team in Munich, joined TVM in April 2001. Prior to that, he spent two years as manager of credit and financial services at Apple Computer and six years as a manager at Ernst & Young in Germany, where he specialised in national and international audits, financial due diligence and German and US GAAP.
TVM, which was founded in 1983 and has offices in Boston and Munich, focuses on venture investments in the information technology and life science sectors. Since formation, it has raised over €1 billion and invested in more than 200 companies in Europe and the US.